OBJECTIVES: For distribution biologic agents in patients with JIA in Russia, data about epidemiology, used drugs and their impact on functional status are necessary. METHODS: Records were examined for 6 months retrospectively. Data were collected via medical chart review by rheumatologists from 11 regions of Russia. Functional status was assessed with CHAQ questionnaire. Inclusion criteria: age (younger than 18 years), minimum 6 months since diagnosis of JIA and availability of 6 months retrospective data. Recruitment: no more than 30% patients received biologic therapy. Disease-specific criteria: about 50% had oligoarthritis, 30-40% - polyarthritis and 10-20% - systemic form. Analysis was performed with methods of descriptive statistic, parametric and non-parametric criteria. RESULTS: Data on 405 patients were obtained. Ratio (male:female) was 1:1.6. Average duration of disease was 5 years. 72% had a disability status caused by JIA. 43% had mild functional disorders; 32% - moderate; 23% - severe disorders, and only 2% had no functional disorders. Seventy-two percent patients in subgroup without functional disorders got biologic therapy, 30% and 28% got biologic agents in subgroups with mild and moderate disorders respectively. In subgroup with severe disorders 41% received biologic therapy; 18% patients with oligoarthritis got  biological agents; 40% - with polyartritis, 54% - with systemic form. CONCLUSIONS: Prescription of biologic therapy increases in case of more severe form of JIA.  Direct relationship between biologic therapy prescription and functional status was not revealed.